Displaying drugs 14876 - 14900 of 15352 in total
2-(3-NITROPHENYL)ACETIC ACID
Experimental
N-(3-AMINOPROPYL)-2-NITROBENZENAMINE
Experimental
Pumosetrag
Pumosetrag has been used in trials studying Gastroesophageal Reflux Disease.
Investigational
Vercirnon
Vercirnon is a novel, orally active anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and ulcerative colitis, the two principal forms of IBD. It is under investigation in clinical trial NCT01611805 (Japanese Phase I of GSK1605786).
Investigational
Matched Description: … anti-inflammatory agent that targets a chemokine receptor protein implicated in both Crohn's disease and …
Cyanamide
A cyanide compound which has been used as a fertilizer, defoliant and in many manufacturing processes. It often occurs as the calcium salt, sometimes also referred to as cyanamide. The citrated calcium salt is used in the treatment of alcoholism. [PubChem]
Experimental
Matched Description: … A cyanide compound which has been used as a fertilizer, defoliant and in many manufacturing processes …
Nitarsone
Nitarsone is an organoarsenic compound. It is used as an additive in poultry feed to improve weight gain and feed efficiency, while preventing blackhead disease. It is marketed as Histostat by Zoetis, a publicly traded subsidiary of Pfizer.
Vet approved
Matched Description: … It is used as an additive in poultry feed to improve weight gain and feed efficiency, while preventing …
4-(2-amino-1,3-thiazol-4-yl)phenol
Experimental
A-620223
Experimental
Sulfabromomethazine
Vet approved
AZD3409
AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.
Investigational
Matched Description: … Phase I trials were initiated January 2003, and were ongoing as of February 2004. …
Beta-hydroxyfentanyl
Experimental
Illicit
Cenerimod
Cenerimod has been used in trials studying the treatment of Systemic Lupus Erythematosus.
Investigational
iCo-007
iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR).
Investigational
Matched Description: … by the formation of new blood vessels (angiogenesis) such as age-related macular degeneration (AMD) and …
Prolectin-M
Prolectin-M is a (1-6)-alpha-D-mannopyranose and acts as an antagonist of galectin. It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).
Investigational
Matched Description: … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. …
Elsubrutinib
Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State).
Investigational
Matched Description: … under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and …
K-00546
Experimental
Displaying drugs 14876 - 14900 of 15352 in total